Huntington Disease – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Huntington Disease – Pipeline Review, H2 2016’, provides an overview of the Huntington Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Huntington Disease

The report reviews pipeline therapeutics for Huntington Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Huntington Disease therapeutics and enlists all their major and minor projects

The report assesses Huntington Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Huntington Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Huntington Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Huntington Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

AFFiRiS AG

Angita BV

Annexon Inc

Astellas Pharma Inc

Azevan Pharmaceuticals Inc

BioCrea GmbH

BrainStorm Cell Therapeutics Inc

Celon Pharma Sp z oo

Chong Kun Dang Pharmaceutical Corp

Diffusion Pharmaceuticals Inc

EncephRx Inc

Evotec AG

Galenea Corp

Genervon Biopharmaceuticals LLC

Horizon Pharma Plc

Immungenetics AG

Ionis Pharmaceuticals Inc

Ipsen SA

Kadmon Corp LLC

KineMed Inc

Krenitsky Pharmaceuticals Inc

Living Cell Technologies Ltd

Medesis Pharma SA

Mitochon Pharmaceuticals Inc

Neuralstem Inc

Neurimmune Holding AG

NeuroNascent Inc

New World Laboratories Inc

nLife Therapeutics SL

NsGene A/S

Omeros Corp

Oryzon Genomics SA

Pfizer Inc

PharmatrophiX Inc

ProQR Therapeutics NV

QR Pharma Inc

reMYND NV

Retrotope Inc

Rhenovia Pharma Ltd

Shire Plc

SOM Biotech SL

Spark Therapeutics Inc

Teva Pharmaceutical Industries Ltd

TyrNovo Ltd

Ultragenyx Pharmaceutical Inc

UniQure NV

Vaccinex Inc

Vertex Pharmaceuticals Inc

VistaGen Therapeutics Inc

Vitality Biopharma Inc

VivaCell Biotechnology Espana SL

Voyager Therapeutics Inc

Vybion Inc

WAVE Life Sciences Ltd

Wellstat Therapeutics Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Huntington Disease Overview 6

Therapeutics Development 7

Huntington Disease - Therapeutics under Development by Companies 9

Huntington Disease - Therapeutics under Investigation by Universities/Institutes 13

Huntington Disease - Pipeline Products Glance 15

Huntington Disease - Products under Development by Companies 18

Huntington Disease - Products under Investigation by Universities/Institutes 23

Huntington Disease - Companies Involved in Therapeutics Development 24

Huntington Disease - Therapeutics Assessment 80

Drug Profiles 91

Huntington Disease - Dormant Projects 260

Huntington Disease - Discontinued Products 268

Huntington Disease - Product Development Milestones 269

Appendix 279

List of Tables

List of Tables

Number of Products under Development for Huntington Disease, H2 2016 19

Number of Products under Development for Huntington Disease – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Development by Companies, H2 2016 (Contd..1) 22

Number of Products under Development by Companies, H2 2016 (Contd..2) 23

Number of Products under Development by Companies, H2 2016 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Development, H2 2016 29

Products under Development by Companies, H2 2016 30

Products under Development by Companies, H2 2016 (Contd..1) 31

Products under Development by Companies, H2 2016 (Contd..2) 32

Products under Development by Companies, H2 2016 (Contd..3) 33

Products under Development by Companies, H2 2016 (Contd..4) 34

Products under Investigation by Universities/Institutes, H2 2016 35

Huntington Disease – Pipeline by Addex Therapeutics Ltd, H2 2016 36

Huntington Disease – Pipeline by AFFiRiS AG, H2 2016 37

Huntington Disease – Pipeline by Angita BV, H2 2016 38

Huntington Disease – Pipeline by Annexon Inc, H2 2016 39

Huntington Disease – Pipeline by Astellas Pharma Inc, H2 2016 40

Huntington Disease – Pipeline by Azevan Pharmaceuticals Inc, H2 2016 41

Huntington Disease – Pipeline by BioCrea GmbH, H2 2016 42

Huntington Disease – Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 43

Huntington Disease – Pipeline by Celon Pharma Sp z oo, H2 2016 44

Huntington Disease – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 45

Huntington Disease – Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 46

Huntington Disease – Pipeline by EncephRx Inc, H2 2016 47

Huntington Disease – Pipeline by Evotec AG, H2 2016 48

Huntington Disease – Pipeline by Galenea Corp, H2 2016 49

Huntington Disease – Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 50

Huntington Disease – Pipeline by Horizon Pharma Plc, H2 2016 51

Huntington Disease – Pipeline by Immungenetics AG, H2 2016 52

Huntington Disease – Pipeline by Ionis Pharmaceuticals Inc, H2 2016 53

Huntington Disease – Pipeline by Ipsen SA, H2 2016 54

Huntington Disease – Pipeline by Kadmon Corp LLC, H2 2016 55

Huntington Disease – Pipeline by KineMed Inc, H2 2016 56

Huntington Disease – Pipeline by Krenitsky Pharmaceuticals Inc, H2 2016 57

Huntington Disease – Pipeline by Living Cell Technologies Ltd, H2 2016 58

Huntington Disease – Pipeline by Medesis Pharma SA, H2 2016 59

Huntington Disease – Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 60

Huntington Disease – Pipeline by Neuralstem Inc, H2 2016 61

Huntington Disease – Pipeline by Neurimmune Holding AG, H2 2016 62

Huntington Disease – Pipeline by NeuroNascent Inc, H2 2016 63

Huntington Disease – Pipeline by New World Laboratories Inc, H2 2016 64

Huntington Disease – Pipeline by nLife Therapeutics SL, H2 2016 65

Huntington Disease – Pipeline by NsGene A/S, H2 2016 66

Huntington Disease – Pipeline by Omeros Corp, H2 2016 67

Huntington Disease – Pipeline by Oryzon Genomics SA, H2 2016 68

Huntington Disease – Pipeline by Pfizer Inc, H2 2016 69

Huntington Disease – Pipeline by PharmatrophiX Inc, H2 2016 70

Huntington Disease – Pipeline by ProQR Therapeutics NV, H2 2016 71

Huntington Disease – Pipeline by QR Pharma Inc, H2 2016 72

Huntington Disease – Pipeline by reMYND NV, H2 2016 73

Huntington Disease – Pipeline by Retrotope Inc, H2 2016 74

Huntington Disease – Pipeline by Rhenovia Pharma Ltd, H2 2016 75

Huntington Disease – Pipeline by Shire Plc, H2 2016 76

Huntington Disease – Pipeline by SOM Biotech SL, H2 2016 77

Huntington Disease – Pipeline by Spark Therapeutics Inc, H2 2016 78

Huntington Disease – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 79

Huntington Disease – Pipeline by TyrNovo Ltd, H2 2016 80

Huntington Disease – Pipeline by Ultragenyx Pharmaceutical Inc, H2 2016 81

Huntington Disease – Pipeline by UniQure NV, H2 2016 82

Huntington Disease – Pipeline by Vaccinex Inc, H2 2016 83

Huntington Disease – Pipeline by Vertex Pharmaceuticals Inc, H2 2016 84

Huntington Disease – Pipeline by VistaGen Therapeutics Inc, H2 2016 85

Huntington Disease – Pipeline by Vitality Biopharma Inc, H2 2016 86

Huntington Disease – Pipeline by VivaCell Biotechnology Espana SL, H2 2016 87

Huntington Disease – Pipeline by Voyager Therapeutics Inc, H2 2016 88

Huntington Disease – Pipeline by Vybion Inc, H2 2016 89

Huntington Disease – Pipeline by WAVE Life Sciences Ltd, H2 2016 90

Huntington Disease – Pipeline by Wellstat Therapeutics Corp, H2 2016 91

Assessment by Monotherapy Products, H2 2016 92

Number of Products by Stage and Target, H2 2016 94

Number of Products by Stage and Mechanism of Action, H2 2016 97

Number of Products by Stage and Route of Administration, H2 2016 100

Number of Products by Stage and Molecule Type, H2 2016 102

Huntington Disease – Dormant Projects, H2 2016 272

Huntington Disease – Dormant Projects (Contd..1), H2 2016 273

Huntington Disease – Dormant Projects (Contd..2), H2 2016 274

Huntington Disease – Dormant Projects (Contd..3), H2 2016 275

Huntington Disease – Dormant Projects (Contd..4), H2 2016 276

Huntington Disease – Dormant Projects (Contd..5), H2 2016 277

Huntington Disease – Dormant Projects (Contd..6), H2 2016 278

Huntington Disease – Dormant Projects (Contd..7), H2 2016 279

Huntington Disease – Discontinued Products, H2 2016 280

List of Figures

List of Figures

Number of Products under Development for Huntington Disease, H2 2016 19

Number of Products under Development for Huntington Disease – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Products, H2 2016 29

Assessment by Monotherapy Products, H2 2016 92

Number of Products by Top 10 Targets, H2 2016 93

Number of Products by Stage and Top 10 Targets, H2 2016 93

Number of Products by Top 10 Mechanism of Actions, H2 2016 96

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 96

Number of Products by Top 10 Routes of Administration, H2 2016 99

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 99

Number of Products by Top 10 Molecule Types, H2 2016 101

Number of Products by Stage and Top 10 Molecule Types, H2 2016 101

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports